Does lipoprotein(a) raise atherothrombotic risk by impairing fibrinolysis and promoting vascular inflammation?

Lipoprotein(a) [Lp(a)] is an independent and causal risk factor for cardiovascular disease, functioning through a unique "triple-threat" mechanism that includes pro-atherogenic, pro-inflammatory, and pro-thrombotic properties. For a 74-year-old male, these mechanisms contribute significantly to the cumulative risk of myocardial infarction and stroke.

Mechanistic evidence for impaired fibrinolysis

The apolipoprotein(a) [apo(a)] component of Lp(a) shares significant structural homology with plasminogen, the precursor to the primary clot-dissolving enzyme, plasmin.

• Structural Mimicry: Apo(a) contains multiple tandem repeats of "kringle" domains, specifically resembling the kringle 4 and 5 domains of plasminogen.
• Competitive Inhibition: Because of this similarity, apo(a) competes with plasminogen for binding sites on fibrin and cell surfaces (such as endothelial cells). By occupying these sites (binding affinity $K_d \approx 33\text{--}100\text{ nM}$), Lp(a) physically blocks plasminogen from being activated by tissue plasminogen activator (tPA).
• Thrombotic Risk: This inhibition of fibrinolysis prevents the efficient breakdown of blood clots, favoring a pro-thrombotic state that can stabilize thrombi on top of ruptured or eroded plaques.

Vascular inflammation and plaque progression

Lp(a) serves as the primary plasma carrier for oxidized phospholipids (OxPL), which are covalently bound to the apo(a) molecule. This relationship drives arterial damage through several pathways:

• Pro-inflammatory Signaling: OxPLs carried by Lp(a) trigger an inflammatory cascade by stimulating monocytes to secrete cytokines such as IL-6, IL-8, and TNF-$\alpha$. These lipids promote M1 macrophage polarization, further intensifying the local inflammatory environment within the arterial wall.
• Plaque Vulnerability: The delivery of OxPL into the vessel wall accelerates the formation of lipid-rich necrotic cores and thinning of the fibrous cap. Imaging studies using PET/CT have demonstrated that patients with elevated Lp(a) and OxPL levels exhibit significantly higher arterial wall inflammation.
• Clinical Correlates: Genetic and clinical data indicate that the OxPL content on Lp(a) is a potent predictor of cardiovascular events, often correlating with elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Bottom line

The claim is fully supported. Lp(a) promotes atherothrombotic risk through dual mechanisms: its structural similarity to plasminogen allows it to inhibit clot dissolution (fibrinolysis), while its role as a carrier for oxidized phospholipids drives the chronic vascular inflammation and plaque instability that lead to cardiovascular events.